New shot could clear eczema in teens – trial underway
NCT ID NCT07042126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main goal is to see if 611 significantly improves skin clearance and reduces itch compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 611 (a lab-made antibody that blocks a protein involved in allergic inflammation)
- What this could lead to
- If successful, this could offer a new treatment option for Chinese adolescents with moderate-to-severe eczema, helping to clear skin and reduce itch.
- What could go wrong
- This is a Phase 3 trial, but results may not apply outside this population. Side effects from blocking IL-4Rα can include injection reactions and infections. The placebo group may also improve.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
RECRUITINGNanchang, Zhejiang, 310003, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
The Fourth Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGJinhua, Zhejiang, 322000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started